Doximity, Inc. (DOCS) Stock: Price, Forecast & Analyst Target
Doximity, Inc. (DOCS) — MoonshotScore 95/100 (Exceptional band), calculated Nov 18, 2026. Price $29.61 (-3.46%), as of the Nov 19, 2026 trading session; market cap $5.28B. Expected results Feb 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Doximity, Inc. · DOCS · NYSE · Healthcare · Medical - Healthcare Information Services
Research dated 2026-09-13: Doximity operates a cloud-hosted platform where physicians, hospital systems, and pharmaceutical companies connect to deliver patient care, share medical information, and conduct professional collaboration. The company monetizes via subscription fees from healthcare organizations and marketing services to pharmaceutical clients; the key question is whether platform adoption and pricing sustain against rising competition and valuation multiples.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Doximity (DOCS)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- EPS beat 6 of the last 8 reports
- Altman Z 23.36 · Piotroski F 6
- ROE 14.8% · ROA 12.8% · current ratio 6.37 · earnings yield 2.4% · free-cash-flow yield 5.1%
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 94 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $29.61 | |
| Change on the day | -3.46% | |
| 52-week range | $17.15–$51.84 | |
| Market capitalisation | $5.28B | — |
| Price / earnings (trailing) | 41.48 | |
| Shares traded on the day | 2.02M | |
| Beta (volatility vs the S&P 500) | 1.29 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Doximity (DOCS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Doximity (DOCS), and what does it report?
Short answer · as of
Doximity's core offering is membership in a professional network serving licensed U.S. practitioners.
Research dated 2026-09-13.
Physicians access peer-to-peer messaging, remote consultation infrastructure, medical literature feeds, and career development tools at no direct cost; the company generates revenue by charging healthcare organizations for administrator accounts and data access, and by selling targeted marketing services to pharmaceutical companies. Operating cash flow reflects cash collected from these subscribers and services minus platform hosting, customer support, and sales expenses. The business model is durable because switching costs are high once adoption embeds clinical workflow.
What do the latest results show for Doximity (DOCS)?
Research dated 2026-09-13.
The most recent quarter showed revenue that exceeded estimates while earnings per share fell slightly short of consensus expectations. Operating cash flow declined from the prior period despite revenue growth, suggesting either timing of cash receipts or higher working capital deployment. Subscription revenue—the majority of total revenue—expanded and represents the most predictable revenue stream. Margins remain elevated, though year-over-year expansion paused from the acceleration of the previous period.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $174.54M Nov 5, 2026
- Latest report · revenue estimate
- $170.84M Nov 5, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 5, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 5, 2026 | $174.54M | $170.84M | $0.3600 | $0.3483 |
| Aug 6, 2026 | $156.62M | $151.77M | $0.2900 | $0.3030 |
| May 13, 2026 | $145.37M | $144.03M | $0.2600 | $0.2800 |
| Feb 5, 2026 | $185.05M | $181.63M | $0.4600 | $0.4400 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $169M | $62M | $0.31 (diluted) |
| Q3 FY2026 | $185M | $62M | $0.31 (diluted) |
| Q4 FY2026 | $145M | $19M | $0.10 (diluted) |
| Q1 FY2027 | $157M | $24M | $0.13 (diluted) |
What are the financial strengths and risks for Doximity (DOCS)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
The balance sheet stands as a fortress with cash that exceeds total debt by an enormous margin, no meaningful interest-bearing obligations, and current assets covering liabilities by a multiple. Operating margins of this magnitude are exceptional and reflect software economics and network effects. The principal financial risk is erosion of competitive moat—either through new entrants fragmenting the physician community or existing platforms (health systems, Microsoft, Amazon) adding physician collaboration features at negligible incremental cost. Valuation multiples suggest markets are pricing in strong competitive headwinds.
What should you watch next at Doximity (DOCS)?
Short answer · as of
The next earnings report is expected on Feb 4, 2027.
Research dated 2026-09-13.
Monitor subscription growth rates and pricing trends to confirm the core platform remains defensible. Watch for platform engagement metrics beyond the financial statements—monthly active users, message volume, time spent—to validate that network stickiness persists as the company matures. Recent analyst downgrades warrant attention as signals of consensus concern around growth deceleration or valuation exhaustion. Cash flow conversion remains the sanity check; if subscription revenue grows but cash collection slows, moat confidence should decline.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Doximity compare with its peers?
Short answer
Doximity's score ranks tied for 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Healthcare social platforms all compete for physician engagement and attention. Doximity's advantage rests on scale—largest physician network in the United States—and the installed base of health systems and pharma customers who have embedded its workflow into procurement and marketing processes. Newer competitors, particularly those backed by AWS or cloud infrastructure giants, carry lower friction cost structures but must build equivalent network density. This creates a race between Doximity's first-mover defensibility and the economics advantage of big tech entrants.
| Company | Price | Market value | Score |
|---|---|---|---|
| $114.53 Nov 18, 2026 | $9.31B | 97 5-pillar Nov 18, 2026 | |
| Doximity (DOCS) — this page | $29.61 | $5.28B | 95 |
| $35.45 Nov 19, 2026 | $2.61B | 95 5-pillar Nov 18, 2026 | |
| $97.31 Nov 18, 2026 | $8.05B | 90 5-pillar Nov 18, 2026 | |
| $64.02 Nov 19, 2026 | $12.7B | 87 5-pillar Nov 18, 2026 | |
| $24.69 Nov 19, 2026 | $3.15B | 79 5-pillar Nov 18, 2026 | |
| $85.80 Nov 19, 2026 | $14.6B | 66 5-pillar Nov 18, 2026 | |
| $60.33 Nov 19, 2026 | $11.5B | 40 5-pillar Nov 18, 2026 | |
| $57.07 Nov 18, 2026 | $7.51B | 38 5-pillar Nov 18, 2026 | |
| $10.68 Nov 19, 2026 | $1.63B | 37 5-pillar Nov 18, 2026 | |
| $19.88 Nov 19, 2026 | $22.8B | 35 5-pillar Nov 18, 2026 | |
| $45.89 Nov 18, 2026 | $4.03B | 35 5-pillar Nov 18, 2026 | |
| $145.14 Nov 18, 2026 | $19.6B | 34 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $23.00 – $41.00
- Consensus target
- $31.75
- Median target
- $32.50
Consensus record · Captured .
Measured against a quoted price of $29.61 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 71
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 12
- Other transactions
- 59
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DOCS in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Fundsmith | Terry Smith | Q3 2026 | 0.10% | $12.37M | Trimmed −33.2% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Doximity (DOCS)?
Doximity Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is the subscription segment so much larger than service revenue?
Subscription revenue reflects fees charged to healthcare organizations and data licensing arrangements, which are recurring and predictable. Service revenue represents marketing services and other offerings that are episodic. The subscription model generates the business durability and earnings consistency; service revenue adds optionality.
How can margins be this high if the company keeps losing estimated earnings?
Operating margins measure cash generation after costs; earnings per share reflects share dilution from equity compensation and one-time charges. The company is cash-generative and profitable by cash accounting, but equity compensation and non-cash items reduce reported net income per share.
Why did operating cash flow decline quarter-over-quarter?
The latest quarter's operating cash flow reflects timing of annual subscription billings and customer payment cycles rather than operational deterioration. Annual subscription renewals create large inflows in certain periods and smaller flows in others. The trailing-twelve-month cash conversion remains strong, and revenue growth continued.
Would a tech giant acquisition of a competitive platform be catastrophic?
New competition from scale-advantaged incumbents is the true structural risk. A Microsoft or Amazon platform feature targeting physicians would draw on existing healthcare relationships and infrastructure. Doximity's network effects and embedded workflow provide some defensibility, but pricing power would face downward pressure if credible alternatives materialized.
What is the DOCS stock price today?
The last price recorded for Doximity, Inc. (DOCS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the DOCS price target?
The analyst consensus price target for Doximity, Inc. (DOCS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 43 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com